Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Total Current Liabilities (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Total Current Liabilities over the past 10 years, most recently at $31.9 million for Q4 2023.

  • For Q4 2023, Total Current Liabilities rose 152.33% year-over-year to $31.9 million; the TTM value through Dec 2023 reached $31.9 million, up 152.33%, while the annual FY2023 figure was $31.9 million, 152.33% up from the prior year.
  • Total Current Liabilities for Q4 2023 was $31.9 million at Corbus Pharmaceuticals Holdings, up from $31.5 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $52.0 million in Q1 2019 and troughed at $12.6 million in Q4 2022.
  • A 5-year average of $26.4 million and a median of $26.5 million in 2019 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 406.4% in 2019 and later plummeted 58.59% in 2021.
  • Year by year, Total Current Liabilities stood at $34.9 million in 2019, then dropped by 8.57% to $31.9 million in 2020, then crashed by 46.68% to $17.0 million in 2021, then dropped by 25.68% to $12.6 million in 2022, then skyrocketed by 152.33% to $31.9 million in 2023.
  • Business Quant data shows Total Current Liabilities for CRBP at $31.9 million in Q4 2023, $31.5 million in Q3 2023, and $16.4 million in Q2 2023.